Menu Search
Equities

BeOne Medicines AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
49BA:FRA

BeOne Medicines AG

Actions
  • Price (EUR)292.00
  • Today's Change0.00 / 0.00%
  • Shares traded4.00
  • 1 Year change+37.74%
  • Beta0.5184
Data delayed at least 15 minutes, as of Feb 13 2026 14:46 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

  • Revenue in USD (TTM)4.97bn
  • Net income in USD68.55m
  • Incorporated2025
  • Employees11.00k
  • Location
    BeOne Medicines AGc/o BeOne Medicines I GmbHAeschengraben 27BASEL 4051SwitzerlandCHE
  • Phone+41 616851900
  • Websitehttps://beonemedicines.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.